Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge?-Reference-Cited by-同舟云学术

Transplant Decisions in Patients with Myelofibrosis: Should Mutations Be the Judge?

Published:2018-04 Issue:4 Volume:24 Page:649-658
ISSN:1083-8791
Container-title:Biology of Blood and Marrow Transplantation
language:en
Short-container-title:Biology of Blood and Marrow Transplantation

Author:

Salit Rachel B.,Deeg H. Joachim

Funder

National Cancer Institute of the National Institutes of Health

Publisher

Elsevier BV

Subject

Transplantation,Hematology

Reference95 articles.

1. Hematopoietic cell transplantation for myelofibrosis: DIPSS plus risk predicts post-transplant outcomes;Samuelson Bannow;Biol Blood Marrow Transplant,2017

2. Indication and management of allogeneic stem cell transplantation in primary myelofibrosis: a consensus process by an EBMT/ELN International Working Group;Kröger;Leukemia,2015

3. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis;Verstovsek;N Engl J Med,2012

4. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis;Harrison;N Engl J Med,2012

5. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis;Passamonti;Blood,2010

Cited by 14 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Understanding triple negative myeloproliferative neoplasms: pathogenesis, clinical features, and management;Leukemia & Lymphoma;2023-11-30

2. Essential Thrombocythemia and Post-Essential Thrombocythemia Myelofibrosis: Updates on Diagnosis, Clinical Aspects, and Management;Laboratory Medicine;2022-08-12

3. Pacritinib for myelofibrosis in adults with thrombocytopenia;Drugs of Today;2022

4. Pretransplant Assessment for Hematopoietic Cell Transplantation Recipients and Donors;Blood and Marrow Transplant Handbook;2021

5. Genomics of MPN progression;Hematology;2020-12-04